From October 1, 2021 to October 31, 2021, the company has repurchased 273,210 shares, representing 0.19% for $9.5 million. With this, the company has completed the repurchase of 22,250,346 shares, representing 15.7% for $550 million under the buyback announced on November 4, 2019.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
50.27 USD | +1.23% | +0.70% | +36.01% |
Jun. 13 | Halozyme Therapeutics Insider Sold Shares Worth $1,006,300, According to a Recent SEC Filing | MT |
Jun. 11 | Halozyme Therapeutics May Seeks M&A | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.01% | 6.32B | |
+14.84% | 122B | |
+18.31% | 113B | |
+3.61% | 22.66B | |
-18.26% | 21.34B | |
-41.55% | 16.92B | |
-14.23% | 16.68B | |
-16.03% | 16.61B | |
-0.68% | 13.62B | |
+21.87% | 11.04B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on November 4, 2019.